Indaptus Therapeutics, Inc. (INDP)
Health Care · Immunotherapy / Immuno-oncology · Nasdaq
Clinical-stage biopharmaceutical company developing novel immunotherapies, including Decoy20, for cancer and other diseases.
What Indaptus Therapeutics, Inc. does
Indaptus Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel immunotherapies. The company's lead product candidate is Decoy20, which is currently in Phase 1 clinical trials with plans for multi-dosing and combination studies. Indaptus operates through a portfolio of research and development programs aimed at addressing unmet medical needs in cancer and other disease areas. As a clinical-stage enterprise with limited operating history, the company is not yet profitable and is dependent on raising additional capital to fund ongoing operations and development activities.
Themes: ["immuno-oncology","cancer immunotherapy","clinical-stage therapeutics","novel biologics"]
Fundamentals
- Price$2.63 as of 2026-07-10 close
- Market cap$298M as of 2026-07-13
- 1-year return-78.7% as of 2026-07-10 close
- ROE-454.0% as of 2026-07-13
- Debt / equity0.00 as of 2026-07-13
- Beta1.13 as of 2026-07-13
Key risks (from latest filing)
["Clinical-stage company with substantial going concern doubts and no current profitability; dependent on successful capital raises to continue operations","Lengthy and uncertain clinical trial processes for Decoy20 and other candidates could result in delays, increased costs, or failure to achieve regulatory approval","Limited cash resources and need for additional capital raises may result in dilution to shareholders and potential loss of technology rights or product candidate commercialization rights"]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.